Evidence map›Paper›PMID 29438092›Full record

Trial reportThe oncologist2018

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.

Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde and 5 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Antibody therapeutics for epithelial ovarian cancer.Expert opinion on biological therapy · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 4 countries.

Joachim von PawelAsklepios Fachkliniken GmbH, Gauting, Germany.
David R SpigelTennessee Oncology, Nashville, Tennessee, USA.
Thomas ErvinFlorida Cancer Specialists, Tampa, Florida, USA.
György LosonczySemmelweis Egyetem, Budapest, Hungary.
Fabrice BarlesiAix Marseille University, Marseille, France.
Erzsébet JuhászOrszágos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary.
Maria AndersonGenentech, Inc., South San Francisco, California, USA.
Bruce McCallGenentech, Inc., South San Francisco, California, USA.
Eric WakshullGenentech, Inc., South San Francisco, California, USA.
Priti HegdeGenentech, Inc., South San Francisco, California, USA.
Weilan YeGenentech, Inc., South San Francisco, California, USA.
Daniel ChenGenentech, Inc., South San Francisco, California, USA.
Ilsung ChangGenentech, Inc., South San Francisco, California, USA.
Ina RheeGenentech, Inc., South San Francisco, California, USA.
Martin ReckLungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany m.reck@lungenclinic.de.
Asklepios Fachkliniken München-Gauting · DEAssistance Publique Hôpitaux de Marseille · FRFlorida Cancer Specialists & Research Institute · USGerman Center for Lung Research · DEOrszágos Korányi Tbc és Pulmonológiai Intézet · HUSemmelweis University · HUTennessee Oncology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

lessons learnedThe lack of efficacy associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populations.Future efforts with agents like anti-EGFL7 should be guided by advances in pharmacodynamic and predictive biomarker development for antiangiogenic agents.

backgroundEpidermal growth factor-like domain 7 (EGFL7) is an extracellular matrix-associated protein that is upregulated during angiogenesis and supports endothelial cell survival. This phase II trial evaluated the efficacy of the anti-EGFL7 antibody, parsatuzumab, in combination with bevacizumab plus platinum-based therapy for advanced or recurrent nonsquamous non-small cell lung cancer (NS-NSCLC).

methodsPatients (

resultsThe progression-free survival (PFS) hazard ratio (HR) was 1.7 (95% confidence interval [CI], 1.0-2.8;

conclusionThere was no evidence of efficacy for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy for first-line NS-NSCLC.

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinCarcinoma, Non-Small-Cell LungDouble-Blind MethodFemaleHumansLung NeoplasmsMaleMiddle AgedPaclitaxelAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabCarboplatinPaclitaxelparsatuzumab

Identifiers

PMID29438092
PMCPMC6067939
OpenAlexW2787205652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.